NCIt definition : A humanized, hinge-stabilized immunoglobulin G4 (IgG4) monoclonal antibody directed
against growth/differentiation factor 15 (GDF-15; macrophage inhibitory cytokine-1;
MIC-1; non-steroidal anti-inflammatory drug-inducible gene-1; NAG-1; placental transforming
growth factor-beta; pTGFB; prostate-derived factor; PDF; placental bone morphogenetic
protein; PLAB), with potential antineoplastic activity. Upon administration, visugromab
specifically targets, binds to and inhibits the activity of GDF-15, which may include
its inhibition of lymphocyte function-associated antigen 1 (LFA-1) activation on CD8
T-cells. This may restore immune cell infiltration into the tumor, leading to tumor
cell killing and inhibition of tumor cell proliferation. GDF-15, a divergent member
of the transforming growth factor-beta (TGF-beta) superfamily of cytokines, is upregulated
in tissue injuries and also secreted by various tumors. It has been linked to immunosuppression
in the tumor microenvironment (TME) and is associated with drug resistance and poor
prognosis.;
UNII : NX3NW9MM9W;
CAS number : 2556646-63-8; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 2556646-63-8
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;
Semantic type(s)